- Open
- 475.00
- High
- 500.00
- Low
- 500.00
- Close
- 500.00
- Change
- -25.00 (-5.26%)
- Volume
- 10
| 25 Jul 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 17 Jun 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 25 Jul 2024 | Annual Report and Accounts (to 2023-12-31) |
4Basebio plc specializes in synthetic enzymatic DNA synthesis for genetic medicines, including cell and gene therapies, DNA and mRNA therapeutics, and vaccines. The company operates a scalable contract manufacturing model, providing GMP-grade synthetic DNA to pharmaceutical and biotech clients transitioning from research to clinical trials and commercialization. With in-house enzyme manufacturing, 4Basebio maintains quality control and rapid product iteration. It serves a diverse customer base of over 125 partners across the biotechnology and pharmaceutical sectors, primarily in the UK and Spain.
| 25 Jul 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 17 Jun 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 25 Jul 2024 | Annual Report and Accounts (to 2023-12-31) |
4Basebio plc specializes in synthetic enzymatic DNA synthesis for genetic medicines, including cell and gene therapies, DNA and mRNA therapeutics, and vaccines. The company operates a scalable contract manufacturing model, providing GMP-grade synthetic DNA to pharmaceutical and biotech clients transitioning from research to clinical trials and commercialization. With in-house enzyme manufacturing, 4Basebio maintains quality control and rapid product iteration. It serves a diverse customer base of over 125 partners across the biotechnology and pharmaceutical sectors, primarily in the UK and Spain.
| 07:00:00 |
| Grant of Options & Director/PDMR Dealing |
| 8 Jul 2026 | 07:00:00 | Director Appointment |
| 15 Jun 2026 |
| 4basebio appoints Johns Hopkins RNA expert to advisory board |
| 20 May 2026 | AIM movers: MP Evans hit by Indonesian restrictions and CT Automotive improves profit |
| 27 Oct 2025 | AIM movers: Conygar Investment sells land to Stena Line and Bioventix hit by weak China revenues |
| 07:00:00 |
| Grant of Options & Director/PDMR Dealing |
| 8 Jul 2026 | 07:00:00 | Director Appointment |
| 15 Jun 2026 |
| 4basebio appoints Johns Hopkins RNA expert to advisory board |
| 20 May 2026 | AIM movers: MP Evans hit by Indonesian restrictions and CT Automotive improves profit |
| 27 Oct 2025 | AIM movers: Conygar Investment sells land to Stena Line and Bioventix hit by weak China revenues |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £348m | -0.4% | |
| £324m | +0.0% | |
4BB4Basebio plc | £78m | -0.5% |
| £22m | -0.1% | |
| £12m | +1.5% | |
| £11m | +0.2% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £348m | -0.4% | |
| £324m | +0.0% | |
4BB4Basebio plc | £78m | -0.5% |
| £22m | -0.1% | |
| £12m | +1.5% | |
| £11m | +0.2% |
